Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.07M | 937.00K | 954.00K | 2.06M | 771.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.56M | 3.08M | 3.50M | 5.48M | 3.12M |
| Operating Income | -2.56M | -3.08M | -3.50M | -5.48M | -3.12M |
| Income Before Tax | -2.21M | -1.87M | -3.45M | -5.18M | -2.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.21M | -1.87M | -3.45M | -5.18M | -2.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.21M | -1.87M | -3.45M | -5.18M | -2.60M |
| EBIT | -2.56M | -3.08M | -3.50M | -5.48M | -3.12M |
| EBITDA | -2.48M | -2.99M | -3.41M | -5.45M | -2.96M |
| EPS Basic | -0.09 | -0.08 | -0.15 | -0.23 | -0.12 |
| Normalized Basic EPS | -0.06 | -0.05 | -0.09 | -0.12 | -0.08 |
| EPS Diluted | -0.09 | -0.08 | -0.15 | -0.23 | -0.12 |
| Normalized Diluted EPS | -0.06 | -0.05 | -0.09 | -0.12 | -0.08 |
| Average Basic Shares Outstanding | 24.05M | 23.86M | 23.76M | 22.49M | 21.28M |
| Average Diluted Shares Outstanding | 24.05M | 23.86M | 23.76M | 22.49M | 21.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |